91制片厂

Skip to main content

Nephrology and Hypertension Research

Contracts, Grants and Sponsored Research

  • The Role of CLIC4 in Angiogenesis.
  • Ion Channel Activity of ApoL1 and its Kidney Disease-Associated Variants.
  • The Channel Activity of ApoL1 and Progressive Chronic Kidney Disease.
  • The Ion Channel Activity of ApoL1 and Podocyte Injury.
  • Cost effectiveness of a decision aid to reduce knowledge barriers to pursuit of live kidney donor transplantation.
  • Interventions to Increase Pancreas Utilization.
  • Effect of Nutrition Education on Dialysis Patient Phosphorus and iPTH Levels.
  • Regulation of Nephron Progenitor Cell Self-Renewal and Differentiation.
  • Regulation of Renal Progenitor Cell Fate in Normal Kidney Development and Townes-Brocks Syndrome.
  • Identifying Genetic Causes of Congenital Renal Disease.
  • Evaluation of RGD Integrin Antagonists for Treatment of Kidney Fibrosis.
  • Contribution of APOL1 to Gestational Hypertension. Low Birth Weight and Prematurity.
  • Long Term Health Outcomes After Live Kidney Donation in African Americans.
  • UCLA (Waterman) Research Services Agreement.
  • Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity.
  • An open-label, prospective randomized, multi-center, Phase II Comparative Trial of Thymoglobulin versus Simulect for the prevention of delayed graft function and acute allograft rejection in renal allograft recipients.
  • Liver transplantation: Patient-reported outcomes, healthcare cost and comparative modeling of the simultaneous liver-kidney allocation policy.
  • Cost effectiveness of a decision aid to reduce knowledge barriers to pursuit of live kidney donor transplantation
  • Modifiable factors affecting live donor disparities (MFALDD).
  • Economic Strategies to Reduce Organ Discard Through Risk-Adjusted Payment Mechanisms.
  • Central artery pressures and waveform analysis in gestational hypertension and preeclampsia.
  • Volume dependency of arterial stiffness.
  • A Randomized, Multi-Country, Multicenter, Double -Blind, Parallel, Placebo-controlled Study of the Effects of Atrasentan on Renal outcomes in Subjects with
  • Type 2 Diabetes and Nephropathy (SONAR study site).
  • Pathophysiological mechanisms of Cardiorenal Syndrome (CRS) with an emphasis on novel treatments targeting bidirectional signaling pathways.